Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors

118

Citations

9

References

2001

Year

Ferry A.L.M. Eskens, Ahmad Awada, David L. Cutler, Maja J.A. de Jonge, Gré P.M. Luyten, M.N. Faber, Paul Statkevich, Alex Sparreboom, Jaap Verweij, Axel‐R. Hanauske,

Journal of Clinical Oncology

Abstract

SCH 66336 can be administered safely using a continuous oral bid dosing regimen. The recommended dose for phase II studies using this regimen is 200 mg bid.

References

	Year	Citations

Page 1